Fortress Biotech, Inc. (FBIO)
FBIONASDAQ-CMBiotechnology: Pharmaceutical Preparations
$1.99
0.0000 (0.00%) today
Pre-market, Nov 9, 4:00 PM ET
- Market cap
- $66.37m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- –
- 52-week range
- $1.79 to $4.53
- Average volume
- 247.0k
- Previous close
- $1.99
Analysts
1 coveringStrong Buy1 buy, 0 hold, 0 sell
Targets a year out average $5.00, +151.3% from here
Earnings
Next report Nov 13, 2026
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $17.63m | $16.08m | $16.04m | $18.72m |
| Gross profit | $11.88m | $10.64m | $9.82m | $12.57m |
| Operating income | -$6.64m | -$4.79m | -$7.74m | -$10.01m |
| Net income | $5.85m | -$3.94m | $110.37m | -$468.0k |
Last four quarters: revenue $68.47m, margin 163.3%, free cash flow –
News
8 latest- Fortress Biotech (FBIO) Q2 2026 Earnings Call TranscriptThe Motley Fool · Aug 13, 2026
- Fortress Biotech Q2 Earnings Call HighlightsMarketBeat · Aug 12, 2026
- Cyprium Therapeutics Closes Sale Of Rare Pediatric Disease PRV For $205 Mln RTTNews · Mar 31, 2026
- After-Hours Earnings Report for March 25, 2026 : JEF, CELC, FUL, EPAC, WS, MLKN, PGEN, BYND, MDV, DERM, FBIO, GCTSNASDAQ.com · Mar 25, 2026
- Fortress Biotech's Cyprium To Sell $205 Million Priority Review Voucher; Shares Rise RTTNews · Feb 23, 2026
- Fortress Biotech's Cyprium To Sell $250 Million Priority Review Voucher; Shares Rise RTTNews · Feb 23, 2026
- Cigna Q4 Earnings Beat Estimates on Higher Specialty VolumesZacks · Feb 5, 2026
- Elevance Health Q4 Earnings Beat Estimates on Increasing PremiumsZacks · Jan 28, 2026
The company
Fortress Biotech, Inc. ('Fortress') is an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income. The company has a portfolio of multiple marketed prescription pharmaceutical products and programs in development at Fortress, at its majority-owned and majority-controlled partners and subsidiaries and at partners and subsidiaries it founded and in which it holds significant minority ownership positions. Fortress' portfolio is being commercialized and developed for various therapeutic areas including oncology, dermatology, and rare diseases. Fortress' model is focused on leveraging its significant biopharmaceutical industry expertise and network to further expand and advance the company's portfolio of product opportunities.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- fortressbiotech.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.